Koronis Pharmaceuticals develops antiviral therapeutics based on Viral Decay Acceleration™ (VDA) - a pioneering treatment approach that offers the possibility of a new therapeutic paradigm. The Company's lead product candidate is KP-1461 for the treatment of HIV.
- Viral Decay Acceleration exploits the strength of a virus – its high mutation rate – to target its collapse. Learn more
- The history behind VDA, the research demonstrating viral collapse, clinical data in HIV and more can be found in the Koronis Compendium Learn more
Viral Decay Acceleration™ Animation
Viral Fitness & Mutagenesis Animation
click the
icon in the player.